ID	Country	Treatment	Phase	Completion	Trial status	Design	Blinding	Arms	Patient setting	Size
2020-001709-21	France	Enoxaparin, tinzaparin, dalteparin, nadroparin	IV	NA	Recruiting	Randomized	Open-label	2	Hospital	550
2020-001823-15	France	Enoxaparin	IV	NA	Recruiting	Single-arm	Open-label	1	ICU	200
2020-001891-14	Spain	Enoxaparin	II	NA	Recruiting	Randomized	Open-label	2	Hospital	140
CHICTR2000030700	China	Enoxaparin	/	2020-Sep	Not recruiting	Randomized	Open-label	2	Hospital	60
CHICTR2000030701	China	Enoxaparin	/	2020-Sep	Not recruiting	Randomized	Open-label	2	Hospital	60
CHICTR2000030946	China	LMW heparin	IV	2020-Apr	Recruiting	Non-randomized	Unspecified	2	Hospital	120
NCT04344756	France	Tinzaparin, enoxaparin, dalteparin, unfractionated heparin	II	2020-Jul	Not recruiting	Randomized	Open-label	2	Hospital, ICU	808
NCT04345848	Switzerland	Enoxaparin Unfractionated heparin	III	2020-Nov	Recruiting	Randomized	Single	2	Hospital, ICU	200
NCT04354155*	United States	Enoxaparin	II	2022-Sept	Not recruiting	Single-arm	Open-label	1	Hospital	38
NCT04359277	United States	Enoxaparin Unfractionated heparin	III	2021-Apr	Recruiting	Randomized	Open-label	2	Hospital	1,000
NCT04360824	United States	Enoxaparin	IV	2021-Apr	Not recruiting	Randomized	Open-label	2	Hospital	170
NCT04362085	Canada	LMW heparin Unfractionated heparin	III	2020-Nov	Recruiting	Randomized	Open-label	2	Hospital	462
NCT04366960	Italy	Enoxaparin	III	2020-Aug	Recruiting	Randomized	Open-label	2	Hospital	2,712
NCT04367831	United States	Enoxaparin Unfractionated heparin	IV	2020-Nov	Recruiting	Randomized	Single	4	ICU	100
NCT04372589	Canada	Enoxaparin, tinzaparin, dalteparin, unfractionated heparin	/	2021-Jan	Not recruiting	Randomized	Open-label	2	Hospital	3,000
NCT04377997	United States	Enoxaparin Unfractionated heparin	II	2021-Jan	Not recruiting	Randomized	Open-label	2	Hospital, ICU	300

Four trials recently approved in Italy and not yet reported in the online registry are not included.

NA, not available; ICU, intensive care unit. *Pediatric subjects.